Today's journal articles

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells.

Immunomodulatory effects of radiofrequency ablation in a breast cancer model.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer (AVAXEL)

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

A Trial of Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type Non-Small-Cell Lung Cancer

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Previous Journal Entries

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers.

Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model.

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.

Biomarkers for predicting the sensitivity of cancer cells to TRAIL-R1 agonistic monoclonal antibody.

Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.

Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.

Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression.

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2.

Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects.

Efficacy of Low-Dose Interferon {alpha}2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of >= 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial.

Characterization of a novel, trastuzumab resistant human breast cancer cell line.

L1-CAM as a target for treatment of cancer with monoclonal antibodies.

Autophagy: novel action of panitumumab in colon cancer.

Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma.

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

Today's News Items

No news items selected today

Training Courses & Meetings

No events listed

Previous News Items

Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma

Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer

---

For faster discovery, automatically organize PubMed results into categories